المؤلفون: Thomas B. Kjeldsen (9920927), František Hubálek (9920930), Tina M. Tagmose (2715901), Lone Pridal (2375119), Hanne H. F. Refsgaard (9920933), Trine Porsgaard (4984634), Sanne Gram-Nielsen (9920936), Lars Hovgaard (3024777), Henrik Valore (9920939), Martin Münzel (1485277), Claudia U. Hjørringgaard (2393773), Claus Bekker Jeppesen (304748), Valentina Manfè (9920942), Thomas Hoeg-Jensen (2052793), Svend Ludvigsen (2945841), Peter Kresten Nielsen (1413532), Inger Lautrup-Larsen (9920945), Carsten E. Stidsen (9193879), Erik M. Wulff (2497318), Patrick W. Garibay (9920948), János T. Kodra (2375125), Erica Nishimura (197646), Peter Madsen (2242984)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Pharmacology, Biotechnology, Infectious Diseases, Computational Biology, Space Science, Chemical Sciences not elsewhere classified, Ultralong pharmacokinetic profiles, phase 2, position B 29, albumin-binding side chain, C 18-based analogues, C 20-based analogues, 14E, ultralong PK profile, 25H, candidates OI 338, insulin receptor affinity, OI 320, Ultralong-Acting Insulin Analogues

Relation: https://figshare.com/articles/journal_contribution/Engineering_of_Orally_Available_Ultralong-Acting_Insulin_Analogues_Discovery_of_OI338_and_OI320/13491056

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c01576.s001